Showing results (51-60 of 59) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Vascular Pharmacology|April 15, 2015
Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic miceAna Luíza Gomes Quinderé, Norma Maria Barros Benevides, Graziano Pelli, et al.European Journal of Clinical Investigation|May 22, 2022
Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistenceArnaud G L'Huillier, Sabrina Pagano, Stephanie Baggio, et al.Obesity Surgery|December 10, 2021
Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort StudySafwaan Adam, Jan H Ho, Yifen Liu, et al.Nature Cardiovascular Research|December 16, 2022
GPR55 in B cells limits atherosclerosis development and regulates plasma cell maturationRaquel Guillamat-Prats, Daniel Hering, Abhishek Derle, et al.Hepatology Communications|November 23, 2025
Interleukin-18 binding protein protects against metabolic steatohepatitisEmmanuel Somm, Yunju Jo, Elodie Perroud, et al.Journal of Clinical Medicine|July 21, 2019
Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary SyndromesNicolas Vuilleumier, Sabrina Pagano, Christophe Combescure, et al.Thrombosis and Haemostasis|November 26, 2011
Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerabilityAlessandra Quercioli, François Mach, Maria Bertolotto, et al.European Journal of Clinical Investigation|July 29, 2021
SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1Sabrina Pagano, Sabine Yerly, Benjamin Meyer, et al.European Heart Journal|November 25, 2011
The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaquesFabrizio Montecucco, Vincenzo Di Marzo, Rafaela F da Silva, et al.Pageof 6